Heron Therapeutics (HRTX) EVP William Forbes Exercises RSUs

What Happened

• William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics (HRTX), had restricted stock units (RSUs) convert to common shares on July 30–31, 2026. He converted 11,769 RSUs on July 30 and 11,694 RSUs on July 31, a total of 23,463 shares.
• To satisfy tax withholding, 3,348 shares were withheld on July 30 and 3,326 on July 31 (6,674 shares total) at $0.50 per share, totaling $3,337 in tax withholding. The filing shows the RSU derivatives converted (reported as derivative dispositions at $0.00) and the withheld shares reported as “F” (payment of exercise price or tax liability).

Key Details

• Transaction dates: July 30, 2026 (11,769 RSUs converted; 3,348 shares withheld), July 31, 2026 (11,694 RSUs converted; 3,326 shares withheld).
• Withholding price / tax payment: $0.50 per share; total withheld value reported = $1,674 (7/30) + $1,663 (7/31) = $3,337.
• Shares acquired via conversion: 23,463 total; shares disposed/withheld for taxes: 6,674 total.
• Shares owned after the reported transactions: not stated in the provided excerpt.
• Footnotes: Each RSU equals one share (F1). Filing notes a grant of 188,315 RSUs (Date of Grant cited as Jan 30, 2026) that vest in 16 equal quarterly installments beginning one quarter after the grant (F2/F3).
• Timeliness: Form 4 was filed Aug 3, 2026 for transactions on July 30–31, 2026; this filing is within the standard reporting window and is not marked late.

Context

• These entries reflect RSU vesting/conversion (transaction code M) and share withholding to cover tax obligations (code F). Withholding of shares for taxes is a routine administrative step and does not necessarily signal buying or selling intent.
• The reported dollar amounts are small (about $3.3k withheld), so this transaction is primarily administrative (vesting + tax withholding), not a market buy or sell.